astrazeneca
The chief executive of pharmaceutical giant AstraZeneca could earn up to £18.7 million (€21.9 million) this year after shareholders approved a motion to increase his pay. Of the shareholders who voted on Thursday, around 64% were in favour of the decision, and 36% were against. Pascal Soriot’s base salary sits at around £1.5 million (€1.76), but he is now able to earn annual incentive payments worth up to 850% of this rate if he hits long-term targets. This compares to his previous incentive allowance of 650%. Since Thursday's vote, Soriot’s annual bonus could also increase to a maximum of 300...
Euronews (English)
Im Prozess um einen mutmaßlichen Corona-Impfschaden hat eine Frau aus Oberfranken einen Teilerfolg gegen den Hersteller Astrazeneca erzielt. Eine Zivilkammer des Oberlandesgericht (OLG) Bamberg verurteilte das Unternehmen zu einer umfassenden Auskunft über Nebenwirkungen seines Corona-Impfstoffs «Vaxzevria», wie ein Gerichtssprecher mitteilte. Der Zivilprozess gehört zu den ersten gegen einen Corona-Impfstoffhersteller in Deutschland. Das Unternehmen muss demnach Daten zu allen bekannten Wirkungen und Nebenwirkungen des Impfstoffs zur Verfügung stellen sowie zu sämtlichen weiteren Erkenntnisse...
DPA (German)
A woman in Germany has achieved an initial victory against the Anglo-Swedish drugmaker AstraZeneca in the trial over suspected harm caused by its Covid-19 jab. The civil case is one of the first in Germany against a coronavirus vaccine manufacturer. A civil chamber of the Bamberg Higher Regional Court, in Bavaria, ordered the company to provide comprehensive information about a possible side effects of its Covid-19 vaccine Vaxzevria. The company must disclose all known side effects of the vaccine as well as on all other findings that may be relevant "insofar as they relate to thrombosis with t...
DPA Breaking News
British pharma company AstraZeneca announced the successful completion of acquiring Gracell Biotechnologies, it said on Thursday. Gracell will now function as a wholly-owned subsidiary of AstraZeneca, with operations in China and the US. According to the definitive agreement, AstraZeneca has purchased all of Gracell's fully diluted share capital through a merger for $2.00 per ordinary share in cash at closing. Additionally, a non-tradable contingent value right of $0.30 per ordinary share in cash will be paid upon reaching a specific regulatory milestone. The initial cash payment accounts for ...
DPA Breaking News
Anglo-Swedish drug major AstraZeneca reported a profit increase in its fourth quarter of $960 million compared to last year's $901 million. Earnings per $0.25 ordinary share were $0.62 compared to $0.58. Core earnings per share (EPS) were $1.45, up 7% at constant exchange rates (CER). Fourth quarter total revenue was $12.02 billion compared to $11.21 billion in the previous year. Total revenue excluding Covid-19 products was $12.04 billion, up 16% at CER. Product sales were $11.32 billion compared to $10.80 billion. Fiscal 2023 core EPS increased 15%, at CER, to $7.26. Total revenue was $45.81...
DPA International
Anglo-Swedish drug major AstraZeneca reported a profit increase in its fourth quarter of $960 million compared to last year's $901 million. Earnings per $0.25 ordinary share were $0.62 compared to $0.58. Core earnings per share (EPS) were $1.45, up 7% at constant exchange rates (CER). Fourth quarter total revenue was $12.02 billion compared to $11.21 billion in the previous year. Total revenue excluding Covid-19 products was $12.04 billion, up 16% at CER. Product sales were $11.32 billion compared to $10.80 billion. Fiscal 2023 core EPS increased 15%, at CER, to $7.26. Total revenue was $45.81...
DPA
The Anglo-Swedish biopharmaceutical company reported $45.8bn (around €41.7bn) in revenue for the financial year 2023 and highlighted strong sales for its cancer drug. It also posted gross profit of more than $37.5bn (around €34bn), up from $32bn (around €29bn) in 2022. The results were driven by oncology drugs, which made up more than a third of sales reported. Why AstraZeneca stock is downHowever, the news failed to cheer investors with the company's stock down 3.76%, at the time of writing. “Many investors view AstraZeneca as invincible given its success in recent years, yet its latest resul...
Euronews (English)
Anglo-Swedish drug major AstraZeneca reported a profit increase in its fourth quarter of $960 million compared to last year's $901 million. Earnings per $0.25 ordinary share were $0.62 compared to $0.58. Core earnings per share (EPS) were $1.45, up 7% at constant exchange rates (CER). Fourth quarter total revenue was $12.02 billion compared to $11.21 billion in the previous year. Total revenue excluding Covid-19 products was $12.04 billion, up 16% at CER. Product sales were $11.32 billion compared to $10.80 billion. Fiscal 2023 core EPS increased 15%, at CER, to $7.26. Total revenue was $45.81...
DPA Breaking News
In hisDaily Market Notes report to investors, Louis Navellier wrote: No fireworks expected: the market closes 3 hours early today and is closed tomorrow. Tesla Stock JumpsStocks are moving slowly today with the exception of Tesla (NASDAQ:TSLA) which has jumped 7% on a beat on vehicle deliveries. It’s helped lift the auto sector in general. On the flip side, AstraZeneca (NASDAQ:AZN) is down 7% after a lung cancer drug trial disappoints. Bond yields are off slightly but still near the highs for the last month. The yield curve remains very inverted with the 2yr/10yr still over 100bps. Crude oil i...
ValueWalk
AstraZeneca plc (LON:AZN)’s first half revenue rose 48% to $22.2bn, ignoring the impact of exchange rates. This reflected growth in all divisions apart from Other Medicines. Excluding the impact of the Alexion acquisition, exchange rates, and other one-off costs, operating profit was 71% higher at £1.4bn. This reflected higher-margin treatments making up a greater proportion of sales, which offset a 33% increase in operating costs. Q2 2022 hedge fund letters, conferences and more A brighter outlook for Covid medicines means the group now expects full year revenue to increase by a low twenties ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら